Express News | Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend Its Reporting Obligations

ReutersMay 9 16:10 ET

Immunome Completes Purchase of AL102, Related Drug Candidate AL101 From Ayala Pharmaceuticals >IMNM

Dow JonesMar 26 08:01 ET

Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome

GlobeNewswireMar 26 08:00 ET

Ayala Completes Patient Enrollment for Pivotal Desmoid Tumor Study

Investing.com Feb 20 10:32 ET

Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

GlobeNewswireFeb 20 08:00 ET

Wedbush Raises Immunome's PT to $27 From $19 on Heels of Announced Plans to Acquire AL101, AL102 From Ayala Pharmaceuticals; Keeps Outperform Rating

MT NewswiresFeb 7 08:53 ET